A mutant impaired in the major high-affinity sulfate transporter SULTR1;2 responsible for uptake in Arabidopsis roots was reported earlier to contain decreased amounts of glutathione 83 but our data indicate that sultr1;2 seedlings exposed to AITC have a WT-like response
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
Consequently, aberrant eating behaviors, such as binge eating and food avoidance, often result from deficits in inhibitory control and other cognitive functions [34]
Heres a quick look: For a direct comparison to prescription options, check out Ozempic vs yerba mate
CVD includes heart disease, heart failure, stroke, and peripheral arterial disease
But of more concern is really that it can cause receptor desensitization, maybe even turn off the whole receptor pathway